C. Jillian Tsai, MD, PhD
@CJTsaiMDPhD
Followers
4K
Following
12K
Media
423
Statuses
4K
Lead, Allan & Ruth Kerbel Palliative RT/Oligomet Program (PROP) @PMcancercentre @RadMedPM @UHN. Via @MSKCancerCenter @MDAndersonNews. HN/skin/metastatic cancers
Toronto, ON, Canada
Joined February 2018
🚨📢🌟 CURB2 Ph3 Trial is activated by @NCICTEP_ClinRes (NCT06686771), built upon CURB Ph2 RCT @TheLancet/@MSKCancerCenter. Appreciate the support of @NRGonc/@SWOG/@CCTG. Pls contact us for activation at your local site❗️ @pmcancercentre @ldawsonmd @DrAlexLouie @HoudaBahig
4
20
72
This is an exceptionally powerful testimony. Patient voices must be central to our work. Their lived experiences offer critical insights that can ultimately improve the relevance, equity, and impact of our research and clinical care.
My goal is to bridge science with the lived experience. And in the context of oligometastatic/progressive/persistent disease, the decision is more than the mutation, the number of sites, and the locations. This is my lung cancer experience condensed in one slide (timeline credit
1
4
21
The most valuable takeaway from the conference was to hear from patient advocates such as @jillfeldman4 to help us realign clinical trial priorities. 🙏
Robust multidisciplinary discussion of oligometastatic NSCLC at #NACLC25 with Drs. @dwightowenmd @maraantonoff @CJTsaiMDPhD and @jillfeldman4. Impressive data but key is patient selection. When does local consolidation add benefit and when does it only add risk?
1
1
14
@jillfeldman4 on what matters most is patient experience. Pts do not fit into boxes and there are metrics beyond survival that matter to patients. “We can’t give patients a double pneumonectomy” and pts want treatments that allow ongoing “living the life that matters to them.”
0
3
5
Robust multidisciplinary discussion of oligometastatic NSCLC at #NACLC25 with Drs. @dwightowenmd @maraantonoff @CJTsaiMDPhD and @jillfeldman4. Impressive data but key is patient selection. When does local consolidation add benefit and when does it only add risk?
2
10
39
I swore an oath to the Constitution in 1986. I've upheld it through 25 years of service and every day since I retired. If Trump's trying to intimidate me, it won’t work. I’ve given too much to our country to be silenced by bullies who care more about power than the Constitution.
17K
10K
65K
When I was 22 years old, I commissioned as an Ensign in the United States Navy and swore an oath to the Constitution. I upheld that oath through flight school, multiple deployments on the USS Midway, 39 combat missions in Operation Desert Storm, test pilot school, four space
33K
26K
144K
Randomized Trial Spine SBRT Target Tumor only vs. Tumor+ Elective Coverage ↑↑tumor control with Elective Target coverage https://t.co/MD9phgu9jw
9
32
74
🌟I logged on to share this important series put forth by @TheLancet 👏👏- worth a read! (but instead got looped in to some mets debate 😅) 🚨Ultra-processed foods: time to put health before profit - The Lancet https://t.co/jBMUAES5kx
1
3
10
📢⭐️New leadership position within @RadMedPM/@pmcancercentre/@UHN: Advanced Practice Radiation Therapist (APRT)! https://t.co/uYffElMTxv 👏 @YatTsang @DKirschMDPhD @ldawsonmd
jobs.smartrecruiters.com
0
3
6
👏👏👏Kudos to @ASTRO_org for putting together a series downloadable PowerPoint presentations for public education. The newly updated #PalliativeCare slides are so informative! https://t.co/ABlc3t5xNY
1
16
50
Thank you @Dan_ChangMD, a long lost 🇨🇦, for visiting @RadMedPM @pmcancercentre @UHN and meeting with our faculty/residents! @MichaelYanMD @ldawsonmd @DKirschMDPhD @ScottBratman @naummalik @ezrahahn
3
2
33
We hope you can join us in Feb at the MultiDisciplinary Head & Neck Cancer Symposium. And if you're there, I'll be speaking on Sat morning as a patient rep sharing my cancer treatment experience. @CJTsaiMDPhD
Registration & housing are now open for the Multidisciplinary Head and Neck Cancers Symposium. Located at the JW Marriott Desert Springs in Palm Desert, CA from February 19-21, 2026. Get the best rate when you register by December 5! #MHNCS26 Register now:
0
2
13
👏#ETHOS #SimFreeSBRT Our team successfully treated a patient with same-day simulation-free SBRT (16Gyx1) to both lesions. The patient was seen in consultation in the morning and went straight to our reserved sim-free treatment slot. This is the future of palliative/oligomet RT!
4
20
109
#HNCancer #SkinCacer #brachytherapy
@naummalik and @YaoCMKL of @pmcancercentre @UHN @RadMedPM @UHN_Otohns performing brachytherapy for skin and HN cancer.
1
2
21
Radiation oncologists are trained to deliver safe, high-precision radiotherapy as part of a #cancer care team. We follow the best available evidence & develop customized, cost-effective plans. Science guides our treatments, but humanity guides our practice. 1/2
In the News: ASTRO marks President Biden’s treatment milestone with ASTRO President Neha Vapiwala, MD leading the treatment team. @NehaVapiwala @SameerKeoleMD @PennMedicine @JoeBiden
https://t.co/9tHLn9zgQt
2
41
239
Happy to see more safe & effective use of radiation therapy to treat @JoeBiden's prostate cancer. Inspired to see the care & expertise of the @PennMedicine team, led by @ASTRO_org's president @NehaVapiwala
@RTAnswers_org has solid info on how RT is used to treat/cure cancers
In the News: ASTRO marks President Biden’s treatment milestone with ASTRO President Neha Vapiwala, MD leading the treatment team. @NehaVapiwala @SameerKeoleMD @PennMedicine @JoeBiden
https://t.co/9tHLn9zgQt
1
2
19
0
2
7
🚨this is an important trial for a relatively rare disease - a collective effort is critical to advance patient care!
The optimal management of oligometastatic HNSCC is a debated and important question. How can we improve *overall survival* in this more favorable population? EA3211 is a phase III randomized trial studying this exact issue. Enrollment is even more streamlined with the most
0
0
3
The optimal management of oligometastatic HNSCC is a debated and important question. How can we improve *overall survival* in this more favorable population? EA3211 is a phase III randomized trial studying this exact issue. Enrollment is even more streamlined with the most
#ClinicalTrial EA3211, led by @DavidSherMD of @utswcancer, aims to improve results for patients with #HeadAndNeckCancer that has spread to a limited number of places. Learn more: https://t.co/8vVaF19FDX
0
11
38
Announcing the keynote speakers for the 2026 Multidisciplinary Head & Neck Cancer Symposium Keynote 1 - Sana Karam, MD, PhD, Washington University "Neoadjuvant Immunotherapy: A Road to Progress - How Far Can It Take Us?" Keynote 2 - David Sher, MD, University of Texas
4
4
15